<DOC>
	<DOC>NCT02128763</DOC>
	<brief_summary>The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.</brief_summary>
	<brief_title>Dry Eye Assessment and Management Study</brief_title>
	<detailed_description>The study is designed to: - Test the hypothesis that omega-3 supplementation is an effective treatment for Dry Eye Disease (DED) in Primary Clinical Trial. - Better understand DED by describing and evaluating a comprehensive set of features of DED and treatment over 12 months of observation in a well-characterized group of patients. - Determine the effects of extended use and discontinuation of omega-3 through the Extension trial.</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Greater than or equal to 2 of the following 4 signs in the same eye at screening and baseline visits (Same signs must be present at Screening and Baseline visits): Conjunctival staining present greater than or equal to 1 (out of possible score of 6 per eye), Corneal fluorescein staining present greater than or equal to 4 (out of a possible score of 15 per eye), Tear film break up time (TBUT) less than or equal to 7 seconds, Schirmer's test greater than or equal to 1 to less than or equal to 7 mm in 5 minutes. Ocular Surface Disease Index (OSDI) score: 2580 at screening, 2180 at baseline. Symptoms of DED for greater than or equal to 6 months. Use of or desire to use artificial tears at least 2 times per day in preceding 2 weeks. Ability to swallow large, soft gelcaps Allergic to ingredients in supplements or placebo Contact lens wear Pregnant, nursing, or lactating Current ocular infection, inflammation, or acute allergic conjunctivitis History of: ocular herpetic keratitis, ocular surgery in past 6 months, LASIK surgery, use of glaucoma medicine or surgery for glaucoma, liver disease, atrial fibrillation, hemophilia or bleeding tendencies Currently on anticoagulation therapy Eyelid abnormalities or extensive ocular scarring Use of EPA/DHA supplements in excess of 1200 mg per dayi Current use, insufficient washout period, or intent to change specific treatments for dry eye disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>